Skip to content

Educational reference only. Not medical advice. Nothing on this site is for sale.

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

Peptide CompendiumLanguageSign in

What's changed

Every update to the site, with its date.

Changes to the site, newest first. News items are listed separately on the News page.

Site updates

October 29, 2026 · v3.10.2: Changelog page and legal-status updates

New "What's changed" page (this page), linked from the footer.
FAQ answers on BPC-157, KPV, MOTS-c, Semax and Epitalon now mention the October 28, 2026 HHS interim compounding policy, matching each page's legal-status section.

October 29, 2026: News ticker and new compound page

A scrolling "Latest" news ticker across the top of every page.
New compound page: dulaglutide (97 compounds in the library).
Legal-status updates on BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon for the October 28, 2026 HHS interim compounding policy.

October 28, 2026 · v3.10.1: Simulator in the menu

The reconstitution Simulator is now in the main menu.
On screens up to 1360px wide, the menu links fold into the Menu button.

October 27, 2026 · v3.10: Research articles

New Articles section: sourced research-desk articles on peptide science, health and policy.
Every version of the site is now backed up, so any earlier version can be restored.

October 2026 · v3.9: News on the home page

News added to the menu, with a "Latest updates" row on the home page.
Illustrated news cards, compact category buttons, guide banners and chart thumbnails.

October 2026 · v3.8: Review tag for new compounds

Newly added compounds carry a "New, under review" tag until they have been checked again.

October 2026 · v3.7: Simulator upgrades

The reconstitution Simulator handles vials up to 10 mL, explains mL versus syringe units, and accepts decimals.
Fixes to the sign-in captcha and to the header overlapping content.

New pages

October 29, 2026: New compound: Dulaglutide
October 29, 2026: New article: Antibiotic candidates in an unlikely place: AI finds 'prionins' hidden inside prion proteins
October 29, 2026: New article: Sport's rulebook catches up with peptides: what the 2027 WADA list changes
October 29, 2026: New article: Amylin's second act: what the petrelintide phase 2 trials tell us
October 29, 2026: New article: From needle to tablet: how peptide drugs learned to survive the gut
October 28, 2026: New compound: Thymalin
October 28, 2026: New compound: Thymulin